Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Revvity IncTrade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs DENTSPLY SIRONA Inc — how do they compare? Revvity Inc trades at $116.02 (market cap $12.91B), while DENTSPLY SIRONA Inc trades at $11.35 (market cap $2.31B). The key difference: Revvity Inc is far larger — about 5.6× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.

RVTYXRAY
Market Cap
$12.91B$2.31B
Sector
TechnologyHealth
52-Week High
$117.75$14.68
52-Week Low
$82.26$9.64
Enterprise Value
$15.23B$4.39B
Dividend Yield
0.24%5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.

Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.

Returns comparison

Trailing returns across standard periods

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY